Tech Company Financing Transactions
Intarcia Therapeutics Funding Round
On 4/1/2014, Intarcia Therapeutics landed $200 million in funding from RA Capital, Farallon Capital Management and Foresite Capital.
Transaction Overview
Company Name
Announced On
4/1/2014
Transaction Type
Venture Equity
Amount
$200,000,000
Round
Undisclosed
Investors
RA Capital (Lead Investor) (Peter Kolchinsky)
New Leaf Venture Partners (James Niedel)
Proceeds Purpose
In this latest transaction, Intarcia further retains control of its lead product candidate ITCA 650 - its novel once-yearly GLP-1 for type two diabetes, currently being investigated in a global phase 3 clinical trial program called FREEDOM.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 Marina Park Dr. 13 Floor
Boston, MA 02210
USA
Boston, MA 02210
USA
Phone
Website
Email Address
Overview
Intarcia Therapeutics, Inc., is a rapidly emerging biopharmaceutical company committed to developing innovative therapies that merge medicine with technology, and have the potential to transform therapeutic categories.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Kurt Graves
Chief Scientific Officer
Andrew Young
VP - Client Services
Jay Smith
VP - General Counsel
Raymond Keane
VP - Human Resources
James Brady
VP - Manufacturing
Thomas Alessi
Browse more venture capital transactions:
Prev: 4/1/2014: SCIenergy venture capital transaction
Next: 4/1/2014: Cima NanoTech venture capital transaction
Share this article
News on VC Transactions
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs